Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Brief Reports   |    
Antipsychotic Formulation and One-Year Rehospitalization of Schizophrenia Patients: A Population-Based Cohort Study
Shiau-Shian Huang, M.D.; Ching-Heng Lin, Ph.D.; El-Wui Loh, Ph.D.; Hsin-yu Yang, M.D.; Chin Hong Chan, M.D., M.A.M.; Tsuo-Hung Lan, M.D., Ph.D.
Psychiatric Services 2013; doi: 10.1176/appi.ps.201200506
View Author and Article Information

Dr. Huang, Dr. Yang, Dr. Chan, and Dr. Lan are with the Department of Psychiatry and Dr. Lin is with the Department of Medical Research, Taichung Veterans General Hospital, No. 160, Sec. 3, Chung-Kang Rd., Taichung 40705, Taiwan (e-mail Dr. Lan: tosafish@gmail.com). Dr. Lan is also with the School of Medicine, National Yang-Ming University, Taipei. Dr. Loh is with Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung City, Taiwan.

Copyright © 2013 by the American Psychiatric Association


Objective  The authors compared the efficacy of long-acting injectable antipsychotics and oral antipsychotics on rehospitalization rate of community-dwelling patients with schizophrenia who had frequent admissions.

Methods  The cohort study of 14,610 patients was conducted by analyzing the Taiwan National Health Research Institutes data. The patients were divided into groups that received oral antipsychotics (risperidone, a different second-generation antipsychotic, or a first-generation antipsychotic) or long-acting injectable antipsychotics (risperidone, haloperidol, or flupenthixol).

Results  One-year rehospitalization rates of the final cohort of 10,552 patients were the same for both groups (by long-acting injection, 27.3%; by oral administration, 27.3%). Secondary analysis of groups receiving long-acting injectable medication showed that haloperidol resulted in lower rehospitalization rates (haloperidol, 22.5%; risperidone, 27.1%; and flupenthixol, 29.5%). Patients’ characteristics, including age, region, and insurance payments were significantly correlated with the risk of relapse (p<.05).

Conclusions  Except for injectable haloperidol, long-acting injectable antipsychotics seem not to be superior to oral antipsychotics in reducing rehospitalization.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
Table 1Rehospitalization rates of 10,552 patients with schizophrenia within one year
Table Footer Note

a Calculated with long-acting injectable haloperidol as the reference



Mojtabai  R;  Lavelle  J;  Gibson  PJ  et al:  Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes.  Schizophrenia Bulletin 29:519–530, 2003
[CrossRef] | [PubMed]
Davis  JM;  Chen  N;  Glick  ID:  A meta-analysis of the efficacy of second-generation antipsychotics.  Archives of General Psychiatry 60:553–564, 2003
[CrossRef] | [PubMed]
Lieberman  JA;  Stroup  TS;  McEvoy  JP  et al:  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  New England Journal of Medicine 353:1209–1223, 2005
[CrossRef] | [PubMed]
Sadock  BJ;  Sadock  VA:  Kaplan & Sadock’s synopsis of psychiatry; in  Behavioral Sciences/Clinical Psychiatry , 10th ed. Edited by Sadock  BJ;  Sadock  VA.  Philadelphia,  Lippincott Williams and Wilkins, 2007
Weiden  PJ;  Schooler  NR;  Weedon  JC  et al:  A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.  Journal of Clinical Psychiatry 70:1397–1406, 2009
[CrossRef] | [PubMed]
Rosenheck  RA;  Krystal  JH;  Lew  R  et al:  Long-acting risperidone and oral antipsychotics in unstable schizophrenia.  New England Journal of Medicine 364:842–851, 2011
[CrossRef] | [PubMed]
Keks  NA;  Ingham  M;  Khan  A  et al:  Long-acting injectable risperidone v olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study.  British Journal of Psychiatry 191:131–139, 2007
[CrossRef] | [PubMed]
Grimaldi-Bensouda  L;  Rouillon  F;  Astruc  B  et al:  Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General Study of Schizophrenia (CGS).  Schizophrenia Research 134:187–194, 2012
[CrossRef] | [PubMed]
Quraishi  S;  David  A:  Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.  Cochrane Database of Systematic Reviews 2:CD001470, 2000
Citrome  L;  Jaffe  A;  Levine  J:  Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.  Schizophrenia Research 119:153–159, 2010
[CrossRef] | [PubMed]
Olfson  M;  Marcus  SC;  Ascher-Svanum  H:  Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.  Schizophrenia Bulletin 33:1379–1387, 2007
[CrossRef] | [PubMed]
Edwards  NC;  Rupnow  MF;  Pashos  CL  et al:  Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.  PharmacoEconomics 23:299–314, 2005
[CrossRef] | [PubMed]
Doering  S;  Müller  E;  Köpcke  W  et al:  Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder.  Schizophrenia Bulletin 24:87–98, 1998
[CrossRef] | [PubMed]
Prince  JD;  Akincigil  A;  Kalay  E  et al:  Psychiatric rehospitalization among elderly persons in the United States.  Psychiatric Services 59:1038–1045, 2008
[CrossRef] | [PubMed]
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles